Roth Capital Seems to Have Lost Some Faith In Q BioMed Inc (QBIO), Downgrades Stocks

Q BioMed Inc. (OTCMKTS:QBIO) Logo

Q BioMed Inc (QBIO) Receives a Downgrade

This morning Q BioMed Inc (QBIO) has been downgraded by Roth Capital to a Hold rating in analysts report issued to clients and investors on Thursday morning. The firm after the upgrade has a $1.8500 target price shares.

The stock increased 7.14% or $0.13 during the last trading session, reaching $1.95. About 38,124 shares traded. Q BioMed Inc. (QBIO) has 0.00% since December 2, 2017 and is . It has underperformed by 15.62% the S&P500.

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company has market cap of $27.77 million. The firm offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer. It currently has negative earnings. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.